ASTELLAS PHARMA UNSP/ADR (ALPMY)
ALPMY moved a median of +0.02% 30 minutes after news, and +0.15% by the close. How ALPMY actually reacts to news — the realized, point-in-time move the market made, measured across 94 labeled events over the last three years with zero look-ahead.
ALPMY’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 35% | 89 |
| 30-min | +0.02% | 50% | 94 |
| 60-min | 0.00% | 48% | 94 |
| to close | +0.15% | 53% | 94 |
| Middle 50% of ALPMY reactions | -0.75% to +0.54% |
|---|---|
| Median reaction (30-min) | +0.02% |
| Measured reactions | 94 |
Half of all ASTELLAS PHARMA UNSP/ADR news events land between -0.75% and +0.54% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ALPMY moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ALPMY's baseline. Nothing else.
Recent ALPMY events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| New Preliminary Real-World VEOZAH™ (fezolinetant) Data Highlights Improvements in Menopause-Related Symptoms and Sleep Outcomes | Press release | PR Newswire | +0.17% | +0.41% | |
| Astellas enters voluntary agreement with U.S. government supporting affordable access to medicines | Press release | PR Newswire | -1.00% | -0.93% | |
| Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma | Press release | PR Newswire | +0.36% | +0.73% | |
| Astellas Announces Five-Year Corporate Strategic Plan to Deliver Greater VALUE Faster for Patients and Position Itself as a Sustainable Growth Company | Press release | PR Newswire | +0.22% | -1.96% | |
| Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026 | Press release | PR Newswire | -0.82% | -1.57% | |
| IZERVAY® (avacincaptad pegol intravitreal solution) Demonstrated Increased Probability of Maintaining Driving Eligibility in Geographic Atrophy Patients | Press release | PR Newswire | +0.51% | +0.68% | |
| Astellas to Highlight New Findings for Geographic Atrophy at ARVO 2026 Annual Meeting | Press release | PR Newswire | +0.62% | +0.63% | |
| VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses | Press release | PR Newswire | +1.22% | +1.36% | |
| Astellas to Present at 44th Annual J.P. Morgan Healthcare Conference | Press release | PR Newswire | +0.00% | -0.07% | |
| Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium | Press release | PR Newswire | +0.27% | +0.13% | |
| Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting | Press release | PR Newswire | +0.00% | +0.47% | |
| Astellas and the Internet's Favorite Grandma, Barbara 'Babs' Costello, Partner to Encourage Others to Get Ahead of Geographic Atrophy (GA) | Press release | PR Newswire | +0.00% | -1.29% | |
| Astellas Presents Preliminary Real-World VEOZAH™ (fezolinetant) Data From OPTION-VMS Phase IV Observational Study | Press release | PR Newswire | +0.00% | +0.52% | |
| PADCEV™ (enfortumab vedotin-ejfv) Plus KEYTRUDA® (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer | Press release | PR Newswire | +0.00% | +0.52% | |
| IZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety | Press release | PR Newswire | -0.14% | -1.89% | |
| Astellas to Present First Real-World VEOZAH™ (fezolinetant) Data at 2025 Annual Meeting of The Menopause Society | Press release | PR Newswire | +0.00% | -3.86% | |
| Astellas to Present New Data on IZERVAY™ (avacincaptad pegol intravitreal solution) in Geographic Atrophy at AAO 2025 Annual Meeting | Press release | PR Newswire | -3.54% | -3.81% | |
| Astellas To Present Pioneering Advances Across Its Portfolio and Pipeline at ESMO 2025 | Press release | PR Newswire | -3.25% | -3.08% | |
| VYLOY® (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric or Gastroesophageal Junction Cancer is now funded in both Ontario and Quebec | Press release | Canada Newswire | -3.25% | -3.08% | |
| Astellas Announces Top Management Personnel Change | Press release | PR Newswire | +0.67% | +3.25% | |
| Astellas Announces a Partnership with the "Korea Institute of Startup and Entrepreneurship Development", an Umbrella Organization of the "Ministry of SMEs and Startups", a Korean Government Agency, for the Operation of the "Partnership with Global Compani | Press release | PR Newswire | -0.19% | +1.30% | |
| XTANDI® (enzalutamide) now funded in Ontario for all approved prostate cancer indications | Press release | Canada Newswire | +0.00% | +3.35% | |
| Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan | Press release | PR Newswire | -0.70% | -3.99% | |
| Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2 | Press release | PR Newswire | +0.00% | -4.66% | |
| Astellas Announces Second Annual Patient Advocacy Organization (PAO) Action Week™ To Empower Patients and Caregivers | Press release | PR Newswire | — | -0.05% | |
| Astellas and MBC BioLabs Announce the 2025 Astellas Future Innovator Prize Awarded to DeepSeq.AI & Serna Bio | Press release | PR Newswire | -0.84% | +0.21% | |
| Astellas Presents New Data that Explores Potential of its Cancer Therapies at 2025 ASCO Annual Meeting | Press release | PR Newswire | +0.00% | +3.35% | |
| Notice of Nominees for Directors | Press release | PR Newswire | -0.84% | -2.17% | |
| Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresses | Press release | PR Newswire | +0.00% | -0.50% | |
| VEOZAH® (fezolinetant film-coated tablets) Now Available in Canada, First and Only Non-hormonal NK3 Antagonist Indicated for Vasomotor Symptoms (VMS) Associated with Menopause | Press release | Canada Newswire | +0.00% | -0.27% | |
| Astellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy Manufacturing | Press release | PR Newswire | +0.00% | +0.10% | |
| New research spotlights global and Canadian perceptions of menopause and the impact of enduring stigma on women's mental health, healthcare and careers | Press release | Canada Newswire | +0.00% | +0.57% | |
| Astellas and MBC BioLabs Announce the Sixth Annual Astellas Future Innovator Prize | Press release | PR Newswire | -0.20% | -0.56% | |
| U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy | Press release | PR Newswire | +0.00% | +0.31% | |
| HeartcoR Solutions Names Healthcare and Pharma Industry Veteran Ciaran Cooper as CEO | Press release | PR Web | +0.00% | -0.26% | |
| Astellas Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan | Press release | PR Newswire | +0.00% | -0.64% | |
| Astellas Makes Announcement about Management Structure | Press release | PR Newswire | +0.00% | -4.34% | |
| Astellas Receives Health Canada Approval for VYLOY® (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer | Press release | Canada Newswire | +0.00% | -4.54% | |
| China's National Medical Products Administration (NMPA) Approves PADCEV™ in combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Bladder Cancer | Press release | PR Newswire | +0.00% | -1.04% | |
| U.S. FDA Confirms Class 1 Resubmission of the Supplemental New Drug Application for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy | Press release | PR Newswire | +0.00% | -4.54% | |
| China's National Medical Products Administration (NMPA) Approves VYLOY™ (zolbetuximab) for First-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Press release | PR Newswire | -0.39% | -1.22% | |
| Astellas and Dr. Jen Ashton launch "Cooler Moments" to Spotlight Menopausal Hot Flashes and Empower Women to Advocate for Themselves | Press release | PR Newswire | +0.29% | +0.57% | |
| VEOZAH® (fezolinetant film-coated tablets) Receives Health Canada Approval as First and Only Non-hormonal Treatment for Vasomotor Symptoms (VMS) Associated with Menopause | Press release | Canada Newswire | +0.37% | +0.28% | |
| Astellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure Management | Press release | PR Newswire | +0.00% | +0.25% | |
| Astellas' VYLOY™ (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer | Press release | PR Newswire | — | -0.38% | |
| Astellas to Present VEOZA™ (fezolinetant) Data at IMS World Congress on Menopause | Press release | PR Newswire | +0.00% | +2.11% | |
| FDA Grants iota Biosciences IDE Approval for First-In-Human Early Feasibility Study with Implantable Bladder Device | Press release | PR Newswire | +0.04% | +0.98% | |
| Astellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other Indications | Press release | PR Newswire | -7.43% | -4.33% | |
| Japan's Ministry of Health, Labour and Welfare Approves PADCEV™ (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Radically Unresectable Urothelial Carcinoma | Press release | PR Newswire | +4.01% | +4.53% | |
| Astellas Receives Approval from the European Commission for VYLOY™ (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer | Press release | PR Newswire | +3.98% | +0.17% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ALPMY section they belong to.
Where else ALPMY is measured.
ALPMY earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Utah Medical Products, Inc. (UTMD) | 96 | 0.00% | 48% |
| Pieris Pharmaceuticals, Inc. (PIRS) | 95 | 0.00% | 39% |
| Check-Cap Ltd. - Ordinary Share (CHEK) | 94 | -0.11% | 42% |
| Titan Pharmaceuticals, Inc. (TTNP) | 94 | +0.47% | 61% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is ASTELLAS PHARMA UNSP/ADR's median reaction calculated?
Every labeled ALPMY news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 94 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of ALPMY's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ALPMY's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.